Treatment outcome and prognostic factors in PCNSL

Diagnostic Pathology

Table 2 The immuno-histochemical findings and treatment outcomes in 43 adult patients with PCNSL

Factor	ORRN (%)	P	CRN (%)	P	Median RFS (Mo)	P	Median OS (Mo)	P
Subtype of DLBCL
- GCB	8/9 (89)	0.637	7/9 (78)	0.136	NR	0.985	NR	0.003
- Non GCB	28/34 (82)	0.637	17/34 (50)	0.136	NR	0.985	14	0.003
BCL6
- Positive	30/37 (81)	0.244	19/37 (51)	0.143	NR	0.842	17	0.534
- Negative	6/6 (100)	0.244	5/6 (83)	0.143	NR	0.842	12	0.534
Non GCB
- Positive MUM1	25/31 (81)	0.401	14/31 (45)	0.070	NR	0.323	14	0.290
- Negative MUM1	3/3 (100)	0.401	3/3 (100)	0.070	NR	0.323	NR	0.290
BCL2
- Positive	32/39 (82)	0.354	21/39 (54)	0.417	17	0.075	15	0.271
- Negative	4/4 (100)	0.354	3/4 (75)	0.417	NR	0.075	NR	0.271
BCL2+ in GCB	5/6 (83)	0.710	4/6 (67)	0.368	NR	0.255	NR	0.061
BCL2+ in non GCB	27/33 (82)	0.710	17/33 (52)	0.368	NR	0.255	14	0.061
MYC ≥40%
- Yes	10/10 (100)	0.111	6/10 (60)	0.761	NR	0.628	17	0.896
- No	26/33 (79)	0.111	18/33 (55)	0.761	NR	0.628	15	0.896
Double-expressor
- Yes	9/9 (100)	0.137	5/9 (56)	0.986	NR	0.628	14	0.834
- No	27/34 (79)	0.137	19/34 (56)	0.986	NR	0.628	17	0.834
Double-expressor
- BCL6+	8/8 (100)	0.167	4/8 (50)	0.714	11	0.374	14	0.503
- BCL6-	28/35 (80)	0.167	20/35 (57)	0.714	NR	0.374	17	0.503
Ki67 ≥ 80%
- Yes	27/33 (82)	0.539	18/33 (55)	0.761	NR	0.790	17	0.897
- No	9/10 (90)	0.539	6/10 (60)	0.761	NR	0.790	14	0.897

Abbreviations: GCB germinal center B cell, ORR overall response rate, CR complete remission rate, PFS progression free survival, OS overall survival, NR not reached

ISSN: 1746-1596